Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer. [electronic resource]
Producer: 20140618Description: 186-94, 196 p. digitalISSN:- 0890-9091
- Animals
- Antibodies, Monoclonal, Humanized -- pharmacokinetics
- Antineoplastic Agents -- pharmacokinetics
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- Drug Approval
- Female
- Humans
- Molecular Targeted Therapy
- Neoadjuvant Therapy
- Receptor, ErbB-2 -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Time Factors
- Treatment Outcome
- United States
- United States Food and Drug Administration
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.